A Phase 4 interventional study of 0.25% bupivacaine in Post op Pain in Hip Surgeries, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by Sohag University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 146 studies testing bupivacaine in Pain — 19 open to participants now, 19 under way, 3 of them phase 3. Bupivacaine · Pain.
Among the 146 studies testing bupivacaine in Pain, this one is the 10th largest by planned enrollment, is one of 6 that started in 2026, is one of 55 in phase 4, reaches primary completion later than 9 of the 18 other live ones, and was the 142nd registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →19 of the 146 studies testing bupivacaine in Pain are open now, in 5 countries. Recruiting first, the newest first:
University of Virginia · Sites in United States
Ages 18+
Tanta University · Sites in Egypt
Ages 18+
Tanta University · Sites in Egypt
Ages 40–75
Ain Shams University · Sites in Egypt
Ages 18–40 · Women only
Children's Hospital of Orange County · Sites in United States
Ages 7–17 · Healthy volunteers
By country, each count listing its studies:
Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
146 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 20 · Phase 3 22 · Phase 4 55
First in 2002; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 63 across the 146 interventional studies. Of the 102 that completed or were terminated, 53 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 146 have an industry lead sponsor. The 10 most frequent:
Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.
Sohag University has 9 studies filed under Pain — fewer than ten, so there is no comparison to draw.
8 of the studies testing bupivacaine in Pain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05964868Phase 3Jessyka LighthallEfficacy of Liposomal Bupivacaine Post Septorhinoplasty | 2026-12 |
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT07631416Sohag UniversityLumbar Erector Spinae Plane Block Versus Fascia Iliaca Plane Block in Hip Surgeries as Postoperative Analgesia | 2026-11-28 |
| NCT06004882M.D. Anderson Cancer CenterPeripheral Nerve Stimulation of Genicular Nerves Versus Conventional Therapy With Intra-articular Steroid Injection for Chronic Knee Pain: A Prospective, Randomized Pilot Study | 2027-01-31 |
| NCT07097493Wake Forest University Health SciencesLiposomal Bupivacaine vs Perineural Adjuvants in Adductor Canalf and iPACK Blocks in Total Knee Arthroplasty | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 146 studies testing bupivacaine in Pain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Lumbar Erector Spinae Plane Block Versus Fascia Iliaca Plane Block in Hip Surgeries as Postoperative Analgesia The aim of this study is to compare the analgesic efficacy of lumbar ElectroSpine Plane Block and Fascia Iliaca Plane Block in patients undergoing hip surgery under spinal anesthesia.
Lumbar Erector Spinae Plane Block Versus Fascia Iliaca Plane Block in Hip Surgeries as Postoperative Analgesia The aim of this study is to compare the analgesic efficacy of lumbar ElectroSpine Plane Block and Fascia Iliaca Plane Block in patients undergoing hip surgery under spinal anesthesia.
Primary outcome:
Secondary outcome:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age between ≥ 18 years
Exclusion Criteria:
Patient refusal
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
20ml of 0.25% bupivacaine will be injected into the interfascial plane between the erector spinae muscle and L5 transverse process.
Drug: 0.25% bupivacaine
a total of 20 mL of 0.25% bupivacaine will be slowly injected in fascia iliaca
Drug: 0.25% bupivacaine
Lumbar Erector Spinae Plane Block Versus Fascia Iliaca Plane Block in Hip Surgeries as Postoperative Analgesia
Also known as: 0.25% isobaric bupivacaine
follow up postoperative pain by Visual Analogue Scale (VAS)score
follow up postoperative pain every 2hours
Time frame: follow up postoperative pain in 24 hours
Requirment of analgesic drugs either (opoid or non opoid) postoprative by Viscual Analogue Scale (VAS) Score
Requirment of analgesic drugs either (opoid or non opoid) postoprative.every 2hours
Time frame: Requirment of analgesic drugs either (opoid or non opoid) postoprative. in 24hours
Plan to share: No — Lumbar Erector Spinae Plane Block Versus Fascia Iliaca Plane Block in Hip Surgeries as Postoperative Analgesia
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Nov 2026, 6 months later.
Of 280 non-industry phase 4 interventional studies under Pain, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's planned 6 months is below that.
Counting every sponsor, half of 295 studies reached it within 18 months; a quarter within 8 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupivacaine